Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Co. Ltd.

Hutchison Whampoa Sinopharm Pharmaceuticals operates as a major distributor and marketing service provider for prescription drugs in China. It leverages the commercial networks of both parent companies to market over 900 third-party pharmaceutical products to hospitals across China. The company does not conduct its own clinical trials but provides a channel for innovative medicines developed by partners such as HUTCHMED/Chi-Med to reach the Chinese market once approved.

The joint venture has enabled significant expansion in sales infrastructure for both domestic and multinational pharma clients seeking access to China's hospital network.

No direct clinical results are reported since it does not run R&D programs itself.

As of December 2022, it had over 860 customers with about $46 million revenue reported in earlier years.

It also serves as a future commercialization vehicle for novel oncology/immunology drugs developed by HUTCHMED/Chi-Med after regulatory approval.

Pipeline breadth/pipeline fields below reflect that this entity itself does not have an R&D pipeline.